This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Roth, J.A. et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2, 985–991 (1996).
Flaman, J.M. et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA 92, 3963–3967 (1995).
Tada, M. et al. Clonality and stability of the p53 gene in human astrocytic tumor cells — quantitative analysis of p53 gene mutations by yeast functional assay. Int. J. Cancer 67, 447–450 (1996).
Temin, H.M. Evolution of cancer genes as a mutation-driven process. Cancer Res. 48, 1697–1701 (1988).
Flaman, J.M. et al. A rapid PCR fidelity assay. Nucleic Acids Res. 22, 3259–3260 (1994).
Finlay, C.A., Hinds, P.W. & Levine, A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083–1093 (1989).
Dittmer, D. et al. Gain of function mutations in p53 . Nature Genet. 4, 42–45 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Estreicher, A., Iggo, R. Retrovirus–mediated p53 gene therapy. Nat Med 2, 1163 (1996). https://doi.org/10.1038/nm1196-1163a
Issue date:
DOI: https://doi.org/10.1038/nm1196-1163a
This article is cited by
-
BRCA1 carries tumor suppressor activity distinct from that of p53 and p21
Cancer Gene Therapy (2001)
-
Retrovirus vectors designed for efficient transduction of cytotoxic or cytostatic genes
Gene Therapy (1999)